Month: July 2024

Record Fiscal 2024 Gross Profit Reduced Net Convertible Debt by ~$300 Million in Fiscal 2024 Fiscal 2024 Net Revenue Reaches $789 Million, Led by Cannabis Net Revenue of $273 Million and Beverage-Alcohol Net Revenue of $202 Million Successfully Executing on Diversified Lifestyle Business Strategy;Tilray Cannabis, Tilray Beverages, Tilray Spirits and Tilray Wellness NEW YORK and LEAMINGTON, Ontario, and NEÜMUNSTER, Germany, July 29, 2024 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray”, “our”, “we” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle consumer packaged goods company elevating lives through moments of connection, today reported financial results for its fourth quarter and fiscal year ended May 31, 2024. Irwin D. Simon, Chairman and Chief Executive Officer, stated, “Tilray Brands is leading the convergence...

MINNEAPOLIS, July 29, 2024 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the second quarter of 2024. Recent HighlightsTotal revenue for the second quarter 2024 was $11.8 million, an increase of 24% over the prior year quarter U.S. Heart Failure (HF) revenue for the second quarter of 2024 was $10.5 million, an increase of 27% over the prior year quarter Active implanting centers in the U.S. were 189, an increase of 35% over the second quarter of 2023 Hired new Chief Revenue Officer and completed expansion of executive leadership team“We are pleased with our solid second quarter results,...

MONACO, July 29, 2024 (GLOBE NEWSWIRE) — Safe Bulkers, Inc. (the “Company”) (NYSE: SB), an international provider of marine drybulk transportation services, announced today its unaudited financial results for the three and six month periods ended June 30, 2024. The Board of Directors of the Company also declared a cash dividend of $0.05 per share of outstanding common stock.Financial highlights            In million U.S. Dollars except per share data Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Six Months 2024 Six Months 2023Net revenues 78.5 81.7 82.3 64.7 70.6 160.2 137.5Net income 27.6 25.3 27.6 15.0 15.4 52.9 34.7Adjusted Net income1 20.3 24.2 29.5 11.1 15.3 44.5 29.5EBITDA2 49.2 47.9 48.8 34.8 34.4 97.1 72.6Adjusted EBITDA2 41.8 46.8 50.7 30.9 34.3 88.7 67.4Earnings per share basic and diluted3 0.24 0.21 0.23 0.12 0.12 0.45 0.27Adjusted...

SAN RAFAEL, Calif., July 29, 2024 (GLOBE NEWSWIRE) — Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company” or “Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and six months ended June 30, 2024. Recent Highlights and AccomplishmentsReported revenues of $5.0 million in the second quarter of 2024 Initial Medicare claims for Ekso Indego Personal are currently pending reimbursement Sold a total of 37 EksoHealth devices in the second quarter of 2024 Achieved gross margin of 53% for the quarter ended June 30, 2024“We are pleased with our significant progress in the second quarter of 2024, highlighted by record sales and the announcement of Centers for Medicare & Medicaid Services’ (“CMS”) national Medicare pricing determination for...

Annual recurring revenues grew 18% year-over-yearSaaS ARR as a percentage of total ARR was approximately 36%Year-to-date cash from operations generated $68.4 million vs. $42.6 million last yearYear-to-date free cash flow generated $67.3 million vs. $40.0 million last year NEW YORK, July 29, 2024 (GLOBE NEWSWIRE) — Varonis Systems, Inc. (Nasdaq: VRNS), a leader in data security, today announced financial results for the second quarter ended June 30, 2024. Yaki Faitelson, Varonis CEO, said, “Our second quarter results reflect the growing momentum of our SaaS platform and recently introduced Managed Data Detection and Response offering, which helps customers automatically prevent data breaches with very little effort.” Guy Melamed, Varonis CFO & COO, added, “The strong adoption of our SaaS platform resulted in 36% of total...

Net interest margin expanded for the second consecutive quarter, and low-cost deposits acquired with the recently completed East Syracuse branch purchase are expected to benefit total funding costs OSWEGO, N.Y., July 29, 2024 (GLOBE NEWSWIRE) — Pathfinder Bancorp, Inc. (“Company”) (NASDAQ: PBHC), the holding company for Pathfinder Bank (“Bank”), announced second quarter 2024 net income available to common shareholders of $2.0 million, or $0.32 per basic and diluted share, consistent with the $2.0 million, or $0.32 per basic and diluted share, earned in the second quarter of 2023. The Company’s total revenue, which is comprised of net interest income, before provision for credit losses, and total noninterest income, for the second quarter of 2024, was $10.7 million, decreasing by $128,000, or 1.2%,...

Achieved record quarterly and first half sepsis test revenue, representing growth of 27% and 25% respectively compared to the prior year periods LEXINGTON, Mass., July 29, 2024 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced financial and operational results for the second quarter ended June 30, 2024. Recent Financial and Operational HighlightsAchieved second quarter 2024 total revenue of $2.0 million, all from sepsis product sales. Achieved record quarterly and first half sepsis test revenue, representing growth of 27% and 25% respectively compared to the prior year periods, led by T2Bacteria® and T2Resistance® panel sales. Executed contracts for 2 T2Dx® Instruments during the second quarter, both...

MENLO PARK, Calif., July 29, 2024 (GLOBE NEWSWIRE) — Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended June 30, 2024. Financial ResultsRevenue of $163.8 million, a 39 percent increase over the same period in 2023 Increase in 2024 revenue guidance to $640 – $670 million, from $620 – $650 million Net income per common share of $0.32 (diluted), compared to $0.25 in second quarter 2023 Cash and investments of $492.5 million as of June 30, 2024“Once again, we had a record number of new Korlym® prescribers and a record number of patients receiving Korlym this quarter. Physicians...